Iqymune

Human normal immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile solution for intravenous use. It provides passive immunity and is used to treat primary and secondary immunodeficiency diseases in patients whose immune systems are compromised.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Iqymune is an immunoglobulin replacement product used to restore humoral immunity in various immunodeficiency conditions.

- Primary immunodeficiency diseases: supplies pooled IgG antibodies to reduce infection frequency and severity. - Secondary immunodeficiency: provides antibody support for patients with acquired immune deficits, such as after chemotherapy or HIV infection. - Bone marrow or stem‑cell transplant recipients: helps reconstitute antibody production during the post‑transplant period.

Common Side Effects: - Headache: mild to moderate pain often occurring during or shortly after infusion. - Fever or chills: transient temperature elevation related to immune activation. - Nausea or vomiting: gastrointestinal discomfort during infusion. - Fatigue: temporary tiredness following administration.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation that may lead to vascular occlusion. - Renal dysfunction: impaired kidney function, especially with high‑dose or rapid infusions. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe thrombocytopenia: markedly low platelet counts increasing bleeding risk.

Before initiating therapy, clinicians should evaluate patient history and baseline immunoglobulin levels. - Assess IgG levels: determine need for replacement and appropriate dosing. - Monitor infusion reactions: observe vital signs and symptoms during and after administration. - Adjust infusion rate: slower rates for patients with cardiovascular disease or prior reactions. - Avoid in patients with known anti‑IgA antibodies and IgA deficiency: risk of severe anaphylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human normal immunoglobulin may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid): - Live vaccines: immunoglobulin can neutralize vaccine efficacy, rendering immunization ineffective. - High‑dose corticosteroids: may increase risk of infection despite immunoglobulin therapy.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., azathioprine, mycophenolate): monitor for additive infection risk. - Anticoagulants (e.g., warfarin): watch for altered bleeding parameters. - Cytotoxic chemotherapy: coordinate timing to avoid overlapping immunosuppression.